Teva Pharmaceutical Industries Ltd. ADR (TEVA)
Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Teva Pharmaceutical's stock is up 69% since December, driven by legal resolution, blockbuster drugs, debt reduction, and new product launches. Recent developments include the launch of biosimilars and generics, positive data on Uzedy and Ajovy, and an accelerated timeline for TEV-48574. Financially, Teva's current ratio is under 1, with upcoming debt maturities posing a challenge. Recommendation remains "Hold" pending Q2 earnings.
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year.
Teva sues Corcept over mifepristone 'monopoly' for rare disorder
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome.
Teva Pharmaceutical: Buy This Bargain Before It's Gone
Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter of 2024. Austedo/Austedo XR sales totaled $282 million in the first three months of 2024, up 65.9% yearly, thanks to its competitive advantage in the fast-growing tardive dyskinesia therapeutics market.
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
